Chemotherapeutic selectivity conferred by selenium: A role for p53-dependent DNA repair

Joshua L. Fischer, Elaine M. Mihelc, Karen Pollok, Martin L. Smith

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Selenium in various chemical forms has been the subject of cancer chemoprevention trials, but, more recently, selenium has been used in combination with DNA-damaging chemotherapeutics. Specifically, selenium protected tissues from dose-limiting toxicity and, in fact, allowed delivery of higher chemotherapeutic doses. At the same time, selenium did not protect cancer cells. Therefore, we seek to define the genetic basis for the observed selectivity of selenium in combination chemotherapeutics. The tumor suppressor p53 is mutated in the vast majority of cancers, but is by definition wild-type in nontarget tissues such as bone marrow and gut epithelium, tissues that are often dose-limiting due to DNA damage. We used primary, low-passage mouse embryonic fibroblasts that are wild-type or null for p53 genes to test differential effects of selenium. Seleno-L-methionine, nontoxic by itself, was used to pretreat cell cultures before exposure to UV radiation or UV-mimetic cancer chemotherapy drugs. Seleno-L-methionine pretreatment caused a DNA repair response, which protected from subsequent challenge with DNA-damaging agents. The observed DNA repair response and subsequent DNA damage protection were p53 dependent as neither was observed in p53-null cells. The data suggest that (a) p53 may be an important genetic determinant that distinguishes normal cells from cancer cells, and (b) combinatorial chemotherapeutics that act by p53-dependent mechanisms may enhance chemotherapeutic efficacy by increasing the chemotherapeutic window distinguishing cancer cells from normal cells.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalMolecular Cancer Therapeutics
Volume6
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Selenium
DNA Repair
Neoplasms
Methionine
DNA Damage
Null Lymphocytes
DNA
p53 Genes
Chemoprevention
Antineoplastic Agents
Epithelium
Cell Culture Techniques
Fibroblasts
Bone Marrow
Radiation

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Chemotherapeutic selectivity conferred by selenium : A role for p53-dependent DNA repair. / Fischer, Joshua L.; Mihelc, Elaine M.; Pollok, Karen; Smith, Martin L.

In: Molecular Cancer Therapeutics, Vol. 6, No. 1, 01.2007, p. 355-361.

Research output: Contribution to journalArticle

Fischer, Joshua L. ; Mihelc, Elaine M. ; Pollok, Karen ; Smith, Martin L. / Chemotherapeutic selectivity conferred by selenium : A role for p53-dependent DNA repair. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 1. pp. 355-361.
@article{6bb9e15300d2445f9a44ef0e09c3f092,
title = "Chemotherapeutic selectivity conferred by selenium: A role for p53-dependent DNA repair",
abstract = "Selenium in various chemical forms has been the subject of cancer chemoprevention trials, but, more recently, selenium has been used in combination with DNA-damaging chemotherapeutics. Specifically, selenium protected tissues from dose-limiting toxicity and, in fact, allowed delivery of higher chemotherapeutic doses. At the same time, selenium did not protect cancer cells. Therefore, we seek to define the genetic basis for the observed selectivity of selenium in combination chemotherapeutics. The tumor suppressor p53 is mutated in the vast majority of cancers, but is by definition wild-type in nontarget tissues such as bone marrow and gut epithelium, tissues that are often dose-limiting due to DNA damage. We used primary, low-passage mouse embryonic fibroblasts that are wild-type or null for p53 genes to test differential effects of selenium. Seleno-L-methionine, nontoxic by itself, was used to pretreat cell cultures before exposure to UV radiation or UV-mimetic cancer chemotherapy drugs. Seleno-L-methionine pretreatment caused a DNA repair response, which protected from subsequent challenge with DNA-damaging agents. The observed DNA repair response and subsequent DNA damage protection were p53 dependent as neither was observed in p53-null cells. The data suggest that (a) p53 may be an important genetic determinant that distinguishes normal cells from cancer cells, and (b) combinatorial chemotherapeutics that act by p53-dependent mechanisms may enhance chemotherapeutic efficacy by increasing the chemotherapeutic window distinguishing cancer cells from normal cells.",
author = "Fischer, {Joshua L.} and Mihelc, {Elaine M.} and Karen Pollok and Smith, {Martin L.}",
year = "2007",
month = "1",
doi = "10.1158/1535-7163.MCT-06-0472",
language = "English",
volume = "6",
pages = "355--361",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Chemotherapeutic selectivity conferred by selenium

T2 - A role for p53-dependent DNA repair

AU - Fischer, Joshua L.

AU - Mihelc, Elaine M.

AU - Pollok, Karen

AU - Smith, Martin L.

PY - 2007/1

Y1 - 2007/1

N2 - Selenium in various chemical forms has been the subject of cancer chemoprevention trials, but, more recently, selenium has been used in combination with DNA-damaging chemotherapeutics. Specifically, selenium protected tissues from dose-limiting toxicity and, in fact, allowed delivery of higher chemotherapeutic doses. At the same time, selenium did not protect cancer cells. Therefore, we seek to define the genetic basis for the observed selectivity of selenium in combination chemotherapeutics. The tumor suppressor p53 is mutated in the vast majority of cancers, but is by definition wild-type in nontarget tissues such as bone marrow and gut epithelium, tissues that are often dose-limiting due to DNA damage. We used primary, low-passage mouse embryonic fibroblasts that are wild-type or null for p53 genes to test differential effects of selenium. Seleno-L-methionine, nontoxic by itself, was used to pretreat cell cultures before exposure to UV radiation or UV-mimetic cancer chemotherapy drugs. Seleno-L-methionine pretreatment caused a DNA repair response, which protected from subsequent challenge with DNA-damaging agents. The observed DNA repair response and subsequent DNA damage protection were p53 dependent as neither was observed in p53-null cells. The data suggest that (a) p53 may be an important genetic determinant that distinguishes normal cells from cancer cells, and (b) combinatorial chemotherapeutics that act by p53-dependent mechanisms may enhance chemotherapeutic efficacy by increasing the chemotherapeutic window distinguishing cancer cells from normal cells.

AB - Selenium in various chemical forms has been the subject of cancer chemoprevention trials, but, more recently, selenium has been used in combination with DNA-damaging chemotherapeutics. Specifically, selenium protected tissues from dose-limiting toxicity and, in fact, allowed delivery of higher chemotherapeutic doses. At the same time, selenium did not protect cancer cells. Therefore, we seek to define the genetic basis for the observed selectivity of selenium in combination chemotherapeutics. The tumor suppressor p53 is mutated in the vast majority of cancers, but is by definition wild-type in nontarget tissues such as bone marrow and gut epithelium, tissues that are often dose-limiting due to DNA damage. We used primary, low-passage mouse embryonic fibroblasts that are wild-type or null for p53 genes to test differential effects of selenium. Seleno-L-methionine, nontoxic by itself, was used to pretreat cell cultures before exposure to UV radiation or UV-mimetic cancer chemotherapy drugs. Seleno-L-methionine pretreatment caused a DNA repair response, which protected from subsequent challenge with DNA-damaging agents. The observed DNA repair response and subsequent DNA damage protection were p53 dependent as neither was observed in p53-null cells. The data suggest that (a) p53 may be an important genetic determinant that distinguishes normal cells from cancer cells, and (b) combinatorial chemotherapeutics that act by p53-dependent mechanisms may enhance chemotherapeutic efficacy by increasing the chemotherapeutic window distinguishing cancer cells from normal cells.

UR - http://www.scopus.com/inward/record.url?scp=33846828457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846828457&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0472

DO - 10.1158/1535-7163.MCT-06-0472

M3 - Article

C2 - 17237294

AN - SCOPUS:33846828457

VL - 6

SP - 355

EP - 361

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -